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Over the last decade, the endocannabinoid system has emerged
as a pivotal mediator of acute and chronic liver injury, with the
description of the role of CB1 and CB2 receptors and their endog-
enous lipidic ligands in various aspects of liver pathophysiology.
A large number of studies have demonstrated that CB1 receptor
antagonists represent an important therapeutic target, owing to
beneﬁcial effects on lipid metabolism and in light of its antiﬁbr-
ogenic properties. Unfortunately, the brain-penetrant CB1 antag-
onist rimonabant, initially approved for the management of
overweight and related cardiometabolic risks, was withdrawn
because of an alarming rate of mood adverse effects. However,
the efﬁcacy of peripherally-restricted CB1 antagonists with lim-
ited brain penetrance has now been validated in preclinical mod-
els of NAFLD, and beneﬁcial effects on ﬁbrosis and its
complications are anticipated. CB2 receptor is currently consid-
ered as a promising anti-inﬂammatory and antiﬁbrogenic target,
although clinical development of CB2 agonists is still awaited. In
this review, we highlight the latest advances on the impact of the
endocannabinoid system on the key steps of chronic liver disease
progression and discuss the therapeutic potential of molecules
targeting cannabinoid receptors.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V.
Introduction
The endocannabinoid system, consisting of cannabinoid recep-
tors, endogenous cannabinoid ligands and their biosynthetic
and degradative enzymes, has recently emerged as an ubiquitous
system with key functions in a variety of physiological settings.
Identiﬁcation of the system was initiated two decades ago with
the characterization of two G protein-coupled receptors, CB1
and CB2 that show high afﬁnity for D9-tetrahydrocannabinol,
the main psychoactive constituent of Cannabis sativa. CB1 recep-
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is highly expressed in the central nervous system, albeit also
present and functional in a wide range of cells and tissues, partic-
ularly in those regulating energy balance [1]. In contrast, CB2
receptor displays a more restricted distribution, predominating
in immune cells, and has been identiﬁed as a major mediator of
anti-inﬂammatory reactions [2]. In addition to phytocannabi-
noids, CB receptors bind to endogenous lipidic ligands, known
as endocannabinoids, among which arachidonoylethanolamide
(anandamide) and 2-arachidonoylglycerol (2-AG) are the most
thoroughly studied. Anandamide exhibits higher afﬁnity for CB1
over CB2 receptors, and 2-AG binds to CB1 and CB2 with similar
afﬁnities. Endocannabinoid synthesis occurs on demand from
distinct cell membrane phopholipid precursors and predomi-
nantly results in paracrine effects. Clearance of anandamide fol-
lows cellular uptake by a speciﬁc transporter, prior to
catabolism by fatty acid amide hydrolase (FAAH), whereas 2-AG
is catabolized by monoacyglycerol lipase (MAGL) [1].
CB1 antagonism attracted considerable interest, owing to the
role of CB1 receptors in the pathogenesis of obesity, via combined
central orexigenic effects, lipogenic effects in adipose tissue, and
reduction of energy expenditure [3]. Unfortunately, approval of
the CB1 antagonist rimonabant for the management of over-
weight and associated co-morbidities was followed by with-
drawal of the drug, because of the alarming incidence of
anxiety, sleeping disorders and depression, and halted develop-
ment programs of other brain penetrant CB1 antagonists.
Research efforts now concentrate on the development of periph-
erally-restricted CB1 receptor antagonists and of CB2 agonists,
devoid of mood regulatory properties.
In the liver, anandamide and 2-AG are present at substantial
levels, and are degraded locally, as indicated by the high expres-
sion of FAAH and MAGL. However, under physiological condi-
tions, the endocannabinoid system is silent, since CB1 and CB2
receptors are faintly expressed. In contrast, induction of CB recep-
tors and/or increased levels of endocannabinoids are common
features of liver injuries of diverse origins [1]. In particular, CB1
receptors are upregulated in hepatocytes, hepatic myoﬁbroblasts
and endothelial cells, whereas CB2 receptors are induced in Kupf-
fer cells and hepatic myoﬁbroblasts, but are not expressed by
hepatocytes. Endocannabinoid levels are increased with varying
patterns depending on the nature of the liver insult, with ananda-
mide being produced mainly by Kupffer cells, and 2-AG by hepa-
tic stellate cells and hepatocytes ([1], see Figs. 1 and 2). In
keeping with these data, a large body of evidence indicates that13 vol. 59 j 891–896
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Fig. 1. Cellular targets of CB1-mediated effects during liver injury. CB1 receptors expressed in hepatocytes and hepatic myoﬁbroblasts contribute to high fat diet and
alcohol-induced steatosis, liver regeneration, and ﬁbrogenesis. Steatogenic properties of CB1 result from hepatocyte activation of lipogenesis, reduction of fatty acid
oxidation, and decreased release of TG-rich VLDL, combined to CB1-dependent release of free fatty acids from the adipose tissue. While anandamide binding to CB1
receptors drives metabolic steatois, 2-AG is the endogenous ligand promoting alcoholic steatosis. CB1 also activates hepatocyte proliferation and promotes ﬁbrogenesis by
enhancing hepatic myoﬁbroblast survival.
Clinical Application of Basic Sciencedysregulation of CB receptor-mediated pathways is the major
determinant in several key aspects of liver pathogenesis. In this
review, we summarize the latest ﬁndings regarding the impact
of cannabinoid signaling in acute and chronic liver injury, and
discuss the possible future clinical development of molecules tar-
geting cannabinoid receptors.CB1-mediated signaling during liver disease
CB1 receptors contribute to the pathogenesis of alcohol-induced
liver disease (ALD), non-alcoholic fatty liver disease (NAFLD),
liver regeneration, ﬁbrogenesis, and cardiovascular alterations
associated with cirrhosis. These effects are mediated by CB1
receptors expressed in hepatocytes, hepatic myoﬁbroblasts,
and endothelial cells, and extrahepatic CB1 receptors, in partic-
ular originating from the adipose tissue and the intestine
(Fig. 1).892 Journal of Hepatology 201Non-alcoholic fatty liver disease
CB1-mediated endocannabinoid tone is enhanced in experimen-
tal diet-induced or genetical models of NAFLD, and is character-
ized by upregulation of adipose tissue and hepatocyte CB1
receptors and increased liver synthesis of anandamide. The
pathogenic role of CB1 receptors in NAFLD is supported by the
resistance to steatosis of obese mice bearing a global or hepato-
cyte-speciﬁc CB1 deletion, or of rodents administered rimona-
bant or AM6545, a CB1 antagonist with limited brain
penetrance [4–6]. Studies in cultured hepatocytes and liver
slices further indicate that the steatogenic properties of CB1
arise from combined hepatocyte activation of SREBP1c-mediated
lipogenesis, reduction of fatty acid oxidation via inhibition of
AMP kinase, and decreased release of TG-rich VLDL [4,5,7]. In
addition, the adipose tissue may largely contribute to the stea-
togenic process via CB1-induced release of free fatty acids by
adipocytes [3,8] (Fig. 1).3 vol. 59 j 891–896
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Fig. 2. Hepatic cellular targets of CB2-mediated protective effects. CB2 receptors expressed in immune cells (Kupffer cells, Th17 lymphocytes) and hepatic
myoﬁbroblasts display anti-inﬂammatory properties and protect against alcohol-induced steatosis, hepatocyte apoptosis, and ﬁbrogenesis. Antiﬁbrogenic properties result
from (i) direct CB2-mediated effects on hepatic myoﬁbroblasts and (ii) indirect hepatoprotective effects on hepatocytes, anti-inﬂammatory properties on Kupffer cell and
downregulation of the production of the proﬁbrogenic cytokine IL17 by Th17 lymphocytes.Pharmacological or genetic inactivation of CB1 receptors is
also associated with a decrease in serum transaminase levels in
obese rodents [5,6]. These observations suggest that besides their
steatogenic properties, hepatocyte CB1 receptors might also
adversely affect hepatocyte survival. Whether reduced hepato-
cyte survival may be a consequence of CB1-mediated activation
of endoplasmic reticulum stress [5] remains to be investigated.
A potential impact of CB1 receptors on the inﬂammatory
response associated with NASH has been suggested by experi-
ments in obese rats, showing that rimonabant reduces liver
inﬂammation [5,6]. The underlying mechanism remains to be
delineated but in hepatocytes, CB1 receptors could contribute
to the acute phase response, via activation of CREBH, a liver-spe-
ciﬁc transcription factor that upregulates acute phase response
genes [9]. In addition, extrahepatic sources of CB1 receptors could
participate in Kupffer cell activation by LPS. Indeed, activation ofJournal of Hepatology 201CB1 receptors in the intestine increases gut permeability and LPS
release in obese mice [10]. In addition, fat CB1 receptors reduce
the production of adiponectin, an adipokine which reduces hepa-
tic inﬂammation [5,6]. In keeping with these data, administration
of rimonabant to obese mice reduces gut permeability and endo-
toxemia, restores adiponectin levels, and improves the hepatic
inﬂammatory response [5,6,10].
Alcohol-induced liver disease
The pathogenic role of CB1 shares striking similarities in ALD and
NAFLD, in keeping with common pathological features of liver
injury. Mice fed an alcohol-enriched diet display enhanced pro-
duction of 2-AG by hepatic stellate cells, resulting in paracrine
induction of CB1 receptors in hepatocytes [11]. As demonstrated
in experimental models of NAFLD, administration of rimonabant3 vol. 59 j 891–896 893
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or genetic ablation of CB1 receptors promotes resistance to alco-
hol-induced steatosis, following combined reduction of lipogene-
sis and enhanced fatty acid oxidation [11].
Liver ﬁbrosis
CB1 receptor expression is upregulated in hepatic myoﬁbroblasts
from cirrhotic patients, and proﬁbrogenic effects of CB1 receptors
expressed in hepatic myoﬁbroblasts were described in mice
undergoing bile duct ligation, chronic exposure to carbon tetra-
chloride or thioacetamide, and in a model of NASH elicited by
prolonged high fat feeding [12,13]. In these models, treatment
with rimonabant or genetic ablation of CB1 receptors reduces
ﬁbrogenesis compared to control animals. Antiﬁbrogenic proper-
ties of CB1 antagonism have been ascribed to growth inhibitory
and proapoptotic effects towards hepatic myoﬁbroblasts [12].
Importantly, CB1 antagonism remains operant at advanced stages
of chronic liver injury, as shown by the therapeutic effects of
rimonabant in rats with full-blown cirrhosis [14].
Liver regeneration
Liver regeneration is associated with a marked induction of CB1
receptors and increased hepatic production of anandamide [15].
Mice administered rimonabant or lacking CB1 either globally or
selectively in hepatocytes, show delayed liver regeneration, as
reﬂected by decreased mitogenic activity of hepatocytes. Reduced
hepatocyte proliferation results from inhibition of cell cycle pro-
teins involved in mitotic progression [15].
Cardiovascular alterations associated with advanced cirrhosis
Endogenous activation of CB1 receptors promote hypotension
and splanchnic vasodilation associated with advanced cirrhosis,
as a consequence of the enhanced production of anandamide
by circulating macrophages and upregulation of CB1 receptors
in endothelial cells and mesenteric arteries of cirrhotic rats
[16]. Blockade of this vasodilatory tone by rimonabant improves
blood pressure, peripheral vascular resistance and portal pres-
sure, and prevents the development of ascites [16].CB2-mediated signaling during liver diseases
CB2 receptors predominantly display protective properties dur-
ing liver injury. These effects largely depend on anti-inﬂamma-
tory and antiﬁbrogenic signals generated by CB2-expressing
hepatic immune cells and/or hepatic myoﬁbroblasts, with para-
crine impact on hepatocytes, which do not express CB2 [1]
(Fig. 2).
Alcoholic and non-alcoholic fatty liver disease
Activation of CB2 receptors in Kupffer cells limits liver inﬂamma-
tion and reduce alcohol-induced liver injury [17]. Indeed, in alco-
hol-fed mice, endogenous or exogenous stimulation of CB2
receptors prevents the switch of Kupffer cells to a proinﬂamma-
tory M1 phenotype, and enhances transition towards the anti-
inﬂammatory M2 phenotype, via a mechanism involving activa-
tion of heme oxygenase-1 [17]. Stimulation of Kupffer cell CB2
receptors also blunts alcohol-induced fat accumulation in hepa-894 Journal of Hepatology 201tocytes. The antisteatogenic signal ensues from the reduced par-
acrine release of steatogenic cytokines (i.e., TNF-a and IL1-b) by
CB2-stimulated Kupffer cells [17].
Strinkingly, CB2 receptors display steatogenic properties in
HFD-fed mice that derive from indirect CB2-mediated increase
in adipose tissue inﬂammation and insulin resistance [18].
Whether CB2 receptors display protective effects against NASH,
as anticipated from their anti-inﬂammatory and hepatoprotec-
tive effects (see below), deserve further studies.
Hepatocyte apoptosis and liver regeneration following acute liver
injury
Endogenous or exogenous activation of CB2 receptors has been
described as a protective pathway in several models of acute liver
injury, in which CB2 receptors undergo early induction in non-
parenchymal cells [2]. Interestingly, and similar to CB2 agonists,
MAGL inhibition also protects against hepatocyte apoptosis elic-
ited by acute liver injury, by enhancing 2-AG-mediated CB2 sig-
naling [19]. Hepatoprotective properties of 2-AG-mediated CB2
effects result from indirect reduction of oxidative/nitrosative
stress in hepatocytes [19,20]. In addition, CB2 receptors
expressed in hepatic myoﬁbroblasts also contribute to liver
regeneration by accelerating proliferation of hepatocytes via a
paracrine interleukin-6 dependent pathway [20].
Hepatocarcinogenesis
Although CB2 receptors are not expressed by hepatocytes, their
expression has been detected in human hepatocarcinoma cell
lines and their activation promote growth inhibition and apopto-
sis of tumor cells, via an autophagy-dependent pathway [21]. In
line with in vitro observations, the CB2 agonist JWH-015 reduces
tumor growth in an orthotopic model of hepatocarcinoma xeno-
graft [21].
Liver ﬁbrosis
In contrast to CB1, CB2 signaling has been identiﬁed as an anti-
ﬁbrogenic pathway. Thus, CB2-deﬁcient mice show enhanced
ﬁbrosis [22], whereas administration of the CB2 agonist JWH-
133 to rats with established cirrhosis improves liver ﬁbrosis
[23]. Antiﬁbrogenic properties of CB2 receptors rely on combined
direct and indirect effects on hepatic myoﬁbroblasts. Indeed, acti-
vation of CB2 receptors in hepatic myoﬁbroblasts reduce their
density, owing to antiproliferative and apoptotic properties
[22]. In addition, CB2 receptors indirectly reduce hepatic myoﬁ-
broblast accumulation via (i) indirect hepatoprotective effects
on hepatocyte survival [20], (ii) anti-inﬂammatory properties of
Kupffer cell CB2 receptors [17] and (iii) downregulation of the
production of the proﬁbrogenic cytokine IL17 by Th17 lympho-
cytes [24] (Fig. 2).CB1 antagonism and CB2 agonism as future approaches for the
management of liver diseases
As depicted in previous sections, numerous experimental evi-
dence supports the key role of the hepatic endocannabinoid sys-
tem in the pathogenesis of liver disease, with CB1 and CB2
receptors often fulﬁlling opposite functions. Enhanced CB1 tone
promotes liver ﬁbrogenesis, cardiovascular alterations associated3 vol. 59 j 891–896
with cirrhosis, and contributes to the pathogenesis of NAFLD and
ALD. On the other hand, upregulated CB2 signaling displays hepa-
toprotective effects, reduces liver inﬂammation, and improves
ALD and liver ﬁbrogenesis. Although experimental results dem-
onstrate deleterious, steatogenic properties of CB2 receptors at
early stages of NAFLD, protective effects against NASH are
expected from their anti-inﬂammatory and hepatoprotective
effects in various experimental models.
Interestingly, available clinical studies inNAFLDandhepatitis C
support the relevance of experimental ﬁndings to human liver dis-
eases. Enhancement of hepatic and extrahepatic endocannabinoid
tones has been documented in several instances, including NAFLD,
chronichepatitis C, andcirrhosis of diverseorigins [1]. Regular can-
nabis use was identiﬁed as an independent predictor of ﬁbrosis
progression [25], indicating that the proﬁbrogenic CB1 signal pre-
vails on the antiﬁbrogenic properties of CB2. The impact of endo-
cannabinoids on NAFLD has been supported in several studies. In
patientswith chronic hepatitis C, daily cannabis use has been iden-
tiﬁed as an independent predictor of steatosis severity [26], and
phase III trials in overweight patients have shown that the CB1
antagonist rimonabant decreases serum transaminases [27], vis-
ceral and liver fat [28]. However, side effects of rimonabant have
precluded further therapeutic development of brain penetrant
inverse CB1 agonists. Nevertheless, encouraging results are
increasingly obtained with second generation peripherally-
restricted CB1 antagonists that appear to retain meaningful thera-
peutic properties for the management of liver diseases. Treatment
of high fat-fed mice with the neutral antagonist AM 6545 induces
weight-independent improvement in fatty liver, glucose homeo-
stasis and plasma lipid proﬁle [5]. Similar effects have been
obtained with JD 5037, an inverse CB1 receptor agonist with lim-
ited brain accessibility [29]. In addition, preliminary results from
our group indicate that AM6545 displays antiﬁbrogenic effects
similar to rimonabant. Future studies should clarify whether, as
recently suggested, neutral antagonist may prove safer in terms
of digestive and psychological side effects.
Key Points
• The endocannabinoid system, consisting of the
cannabinoid receptors, endogenous cannabinoid
ligands and their biosynthetic and degradative
enzymes, is a key mediator of acute and chronic liver
injury
• CB1 receptors participate in the pathogenesis of ALD
and NAFLD, promote liver regeneration and accelerate
liver fibrogenesis
• CB2 receptors exert hepatoprotective effects, reduce
alcohol-induced liver inflammation and injury, and
display antifibrogenic properties 
• Antagonism of CB1 receptors and CB2 receptor
agonism have been identified as promising therapeutic
strategies for the management of liver diseasesConclusions
Overwhelming evidence supports the therapeutic potential of
peripherally-restricted CB1 antagonists and CB2 agonists in theJournal of Hepatology 201management of chronic liver diseases. A major interest of this
approach resides in the multiple levels of action of these thera-
peutic strategies on various steps of chronic liver disease progres-
sion. Exciting therapeutic developments are now anticipated
from the development of the second generation of neutral and
inverse peripherally-restricted CB1 antagonists that show prom-
ising effects in preclinical studies. However, long-term studies
are required to conﬁrm the absence of central effects of these
new molecules in both experimental models and humans. Based
on the promising protective effects of CB2 receptor agonists on
various steps of acute and chronic liver disease progression, the
development of stable CB2 agonists is also eagerly awaited.
Whether the potential of CB2 and CB1-based therapeutics can
be turned to reality will be the challenge of the next few years.Financial support
This work was supported by the INSERM, the Université Paris-Est,
312 and by grants (to S.L.) of the Agence Nationale de la
Recherche.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
References
[1] Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S. The endocan-
nabinoid system as a key mediator during liver diseases: new insights and
therapeutic openings. Br J Pharmacol 2011;163:1432–1440.
[2] Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S,
et al. CB2 receptors as new therapeutic targets during liver diseases. Br J
Pharmacol 2008;153:286–289.
[3] Matias I, Di Marzo V. Endocannabinoids and the control of energy balance.
Trends Endocrinol Metab 2007;18:27–37.
[4] Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, et al.
Hepatic CB1 receptor is required for development of diet-induced steatosis,
dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest
2008;118:3160–3169.
[5] Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al.
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic
risk in mouse models of obesity. J Clin Invest 2010;120:2953–2966.
[6] Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C,
et al. Rimonabant reduces obesity-associated hepatic steatosis and features
of metabolic syndrome in obese Zucker fa/fa rats. Hepatology
2007;46:122–129.
[7] Jourdan T, Demizieux L, Gresti J, Djaouti L, Gaba L, Verges B, et al.
Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver
lipid metabolism in mice: evidence from cultured explants. Hepatology
2012;55:790–799.
[8] Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P. CB1
antagonism exerts speciﬁc molecular effects on visceral and subcutaneous
fat and reverses liver steatosis in diet-induced obese mice. Diabetes
2010;59:926–934.
[9] Chanda D, Kim DK, Li T, Kim YH, Koo SH, Lee CH, et al. Cannabinoid receptor
type 1 (CB1R) signaling regulates hepatic gluconeogenesis via induction of
endoplasmic reticulum-bound transcription factor cAMP-responsive ele-
ment-binding protein H (CREBH) in primary hepatocytes. J Biol Chem
2011;286:27971–27979.
[10] Muccioli GG, Naslain D, Backhed F, Reigstad CS, Lambert DM, Delzenne NM,
et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol
Syst Biol 2010;6:392.
[11] Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, Mukhopadhyay P, et al.
Paracrine activation of hepatic CB(1) receptors by stellate cell-derived
endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008;7:
227–235.3 vol. 59 j 891–896 895
Clinical Application of Basic Science
[12] Teixeira-Clerc F, Julien B, Grenard P, Tran-Van-Nhieu J, Deveaux V, Serriere-
Lanneau V, et al. CB1 cannabinoid receptor antagonism: a novel strategy for
the treatment of liver ﬁbrosis. Nat Med 2006;12:671–676.
[13] DeLeve LD, Wang X, Kanel GC, Atkinson RD, McCuskey RS. Prevention of
hepatic ﬁbrosis in a murine model of metabolic syndrome with nonalcoholic
steatohepatitis. Am J Pathol 2008;173:993–1001.
[14] Giannone FA, Baldassarre M, Domenicali M, Zaccherini G, Trevisani F,
Bernardi M, et al. Reversal of liver ﬁbrosis by the antagonism of endocan-
nabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis.
Lab Invest 2012;92:384–395.
[15] Mukhopadhyay B, Cinar R, Yin S, Liu J, Tam J, Godlewski G, et al.
Hyperactivation of anandamide synthesis and regulation of cell-cycle
progression via cannabinoid type 1 (CB1) receptors in the regenerating
liver. Proc Natl Acad Sci U S A 2011;108:6323–6328.
[16] Moezi L, Gaskari SA, Lee SS. Endocannabinoids and liver disease. V.
endocannabinoids as mediators of vascular and cardiac abnormalities in
cirrhosis. Am J Physiol Gastrointest Liver Physiol 2008;295:G649–G653.
[17] Louvet A, Teixeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, Zimmer A,
et al. Cannabinoid CB2 receptors protect against alcoholic liver disease by
regulating Kupffer cell polarization in mice. Hepatology 2011;54:
1217–1226.
[18] Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S,
et al. Cannabinoid CB2 receptor potentiates obesity-associated inﬂamma-
tion, insulin resistance and hepatic steatosis. PLoS One 2009;4:e5844.
[19] Cao Z, Mulvihill MM, Mukhopadhyay P, Xu H, Erdelyi K, Hao E, et al.
Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling
and hepatic injury in mice. Gastroenterology 2013;144:808–817.
[20] Teixeira-Clerc F, Belot MP, Manin S, Deveaux V, Cadoudal T, Chobert MN,
et al. Beneﬁcial paracrine effects of cannabinoid receptor 2 on liver injury
and regeneration. Hepatology 2010;52:1046–1059.896 Journal of Hepatology 201[21] Vara D, Salazar M, Olea-Herrero N, Guzman M, Velasco G, Diaz-Laviada I.
Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of
AMPK-dependent activation of autophagy. Cell Death Differ 2011;18:
1099–1111.
[22] Julien B, Grenard P, Teixeira-Clerc F, Tran-Van-Nhieu J, Li L, Karzak M, et al.
Antiﬁbrogenic role of the cannabinoid receptor CB2 in the liver. Gastroen-
terology 2005;128:742–755.
[23] Munoz-Luque J, Ros J, Fernandez-Varo G, Tugues S, Morales-Ruiz M, Alvarez
CE, et al. Regression of ﬁbrosis after chronic stimulation of cannabinoid CB2
receptor in cirrhotic rats. J Pharmacol Exp Ther 2008;324:475–483.
[24] Lafdil F, Guillot A, Bizy A, Zoltani K, Deveaux V, Zafrani S, et al. Inhibition of
the pro-ﬁbrogenic Th17 immune response by cannabinoid receptor 2
agonist decreases liver ﬁbrosis. J Hepatol 2012;56, S152–S152.
[25] Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al.
Daily cannabis smoking as a risk factor for ﬁbrosis progression in chronic
hepatitis C. Hepatology 2005;42:63–71.
[26] Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-
Alias M, et al. Daily cannabis use: a novel risk factor of steatosis severity in
patients with chronic hepatitis C. Gastroenterology 2008;134:432–439.
[27] Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O. Long-
term effect of CB1 blockade with rimonabant on cardiometabolic risk
factors: two year results from the RIO-Europe Study. Eur Heart J
2008;29:1761–1771.
[28] Despres JP, Ross R, Boka G, Almeras N, Lemieux I. Effect of rimonabant on the
high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adi-
posity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol
2009;29:416–423.
[29] Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, et al. Peripheral
cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin
resistance. Cell Metab 2012;16:167–179.3 vol. 59 j 891–896
